

Resolution  
by the Federal Joint Committee  
on the discontinuation of benefit assessments of pharmaceuticals  
on the existing market

from 17 April 2014

In its session on 17 April 2014, the Federal Joint Committee resolved the following:

Following the annulment of the German Social Code, Book Five (SGB V), section 35a, paragraph 6 through the 14th SGB V amendment, article 1, number 1 from 27 March 2014 (Federal Law Gazette I, p. 261),

1. The benefit assessment of pharmaceuticals with new active ingredients on the existing market instigated by the resolutions of 18 April 2013 and 14 November 2013 and
  2. The benefit assessment of the active ingredient saxagliptin initiated on 1 September 2013
- shall be discontinued.

The justification for this resolution will be published on the website of the Federal Joint Committee at [www.g-ba.de](http://www.g-ba.de).

Berlin, 17 April 2014

The Federal Joint Committee in  
accordance with SGB V, section 91

The Chair  
Hecken